DIA
ECYT

Denver Investment Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Denver Investment Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,601
Closed -$39K – 522
2016
Q3 		$39K Sell
12,601
-904
-7% -$2.82K ﹤0.01% 440
2016
Q2 		$43K Sell
13,505
-2,831
-17% -$10.4K ﹤0.01% 453
2016
Q1 		$51K Sell
16,336
-5,187
-24% -$16.9K ﹤0.01% 460
2015
Q4 		$86K Buy
+21,523
New +$99.1K ﹤0.01% 489

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Denver Investment Advisors's ECYT Position: Q4 2016 in Review

Denver Investment Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2016, closing a stake of 12,601 shares — an estimated $39K sold.

Denver Investment Advisors first reported a position in ECYT in Q4 2015 and held it in 4 quarters. The position peaked at $86K in Q4 2015. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

  • Denver Investment Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Denver Investment Advisors sold 12,601 Endocyte, Inc. Common Stock shares in Q4 2016, an estimated $39K.
  • Denver Investment Advisors first reported a position in Endocyte, Inc. Common Stock in Q4 2015 and held it in 4 quarters.
  • Denver Investment Advisors's Endocyte, Inc. Common Stock position peaked at $86K in Q4 2015.
  • 96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on Denver Investment Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.